Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation‑eligible hepatocellular carcinoma (EMERALD‑3): a global, randomised, open‑label, sponsor‑blinded, phase 3 study

Cancer research · Hepatocellular carcinoma

"The primary endpoint was progression‑free survival for STRIDE plus lenvatinib plus TACE versus TACE."

This phase 3, randomised, open‑label, sponsor‑blinded study evaluated the efficacy and safety of a STRIDE regimen (durvalumab plus tremelimumab) with or without lenvatinib, combined with transarterial chemoembolisation (TACE), vs TACE alone in adults with embolisation‑eligible hepatocellular carcinoma (HCC). The primary endpoint was progression‑free survival (PFS) for STRIDE plus lenvatinib plus TACE versus TACE. Secondary endpoints included overall survival (OS) for STRIDE plus lenvatinib plus TACE versus TACE, and PFS and OS for STRIDE plus TACE versus TACE. At the data cutoff of February 23, 2026, median PFS was 13.7 months for STRIDE plus lenvatinib plus TACE versus 9.8 months for TACE (HR 0.70; 95% CI 0.57‑0.86; p = 0.0007). Median OS was 39.5 months for STRIDE plus lenvatinib plus TACE versus 34.7 months for TACE (HR 0.84; 95% CI 0.65‑1.09; p = 0.18).

This study provides evidence that adding an immunotherapy‑and‑targeted‑therapy combination to standard TACE improves progression‑free survival in patients with hepatocellular carcinoma who are eligible for embolisation, potentially establishing a new standard of care for this population.

Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.

Original source

Related signals